Research programme: vaccines - CyTuVax

Drug Profile

Research programme: vaccines - CyTuVax

Alternative Names: PanCaVax

Latest Information Update: 20 Nov 2015

Price : $50

At a glance

  • Originator CyTuVax
  • Class Vaccines
  • Mechanism of Action Immunogenetic stimulants; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Preclinical Cytomegalovirus infections; Malignant melanoma; Pancreatic cancer

Most Recent Events

  • 20 Nov 2015 Preclinical trials in Pancreatic cancer in Netherlands (unspecified route)
  • 20 Nov 2015 Preclinical trials in Malignant melanoma in Netherlands (unspecified route)
  • 20 Nov 2015 Preclinical trials in Cytomegalovirus infections (Prevention) in Netherlands (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top